Flurizan

NSAID,inhibits γ-secretase activity CAS# 51543-40-9

Flurizan

Catalog No. BCC2342----Order now to get a substantial discount!

Product Name & Size Price Stock
Flurizan: 5mg $17 In Stock
Flurizan: 10mg Please Inquire In Stock
Flurizan: 20mg Please Inquire Please Inquire
Flurizan: 50mg Please Inquire Please Inquire
Flurizan: 100mg Please Inquire Please Inquire
Flurizan: 200mg Please Inquire Please Inquire
Flurizan: 500mg Please Inquire Please Inquire
Flurizan: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Flurizan

Number of papers citing our products

Chemical structure

Flurizan

3D structure

Chemical Properties of Flurizan

Cas No. 51543-40-9 SDF Download SDF
PubChem ID 92337 Appearance Powder
Formula C15H13FO2 M.Wt 244.26
Type of Compound N/A Storage Desiccate at -20°C
Synonyms (<em>R</em>)-Flurbiprofen
Solubility DMSO : ≥ 50 mg/mL (204.70 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name (2R)-2-(3-fluoro-4-phenylphenyl)propanoic acid
SMILES CC(C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O
Standard InChIKey SYTBZMRGLBWNTM-SNVBAGLBSA-N
Standard InChI InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)/t10-/m1/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Flurizan

DescriptionNonsteroidal anti-inflammatory drug (NSAID) that inhibits γ-secretase activity. Selectively lowers Aβ42 levels in human neuroglioma cells; displays no effect on Aβ40 levels at a concentration of 100 μM.

Flurizan Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Flurizan Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Flurizan

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 4.094 mL 20.47 mL 40.94 mL 81.88 mL 102.35 mL
5 mM 0.8188 mL 4.094 mL 8.188 mL 16.376 mL 20.47 mL
10 mM 0.4094 mL 2.047 mL 4.094 mL 8.188 mL 10.235 mL
50 mM 0.0819 mL 0.4094 mL 0.8188 mL 1.6376 mL 2.047 mL
100 mM 0.0409 mL 0.2047 mL 0.4094 mL 0.8188 mL 1.0235 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Flurizan

Nonsteroidal anti-inflammatory drug (NSAID) that inhibits γ-secretase activity. Selectively lowers Aβ42 levels in human neuroglioma cells; displays no effect on Aβ40 levels at a concentration of 100 μM.

Featured Products
New Products
 

References on Flurizan

Hierarchical Bayesian cognitive processing models to analyze clinical trial data.[Pubmed:23123230]

Alzheimers Dement. 2013 Jul;9(4):422-8.

Identifying disease-modifying treatment effects in earlier stages of Alzheimer's disease (AD)-when changes are subtle-will require improved trial design and more sensitive analytical methods. We applied hierarchical Bayesian analysis with cognitive processing (HBCP) models to the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) and MCI (mild cognitive impairment) Screen word list memory task data from 14 Alzheimer's disease AD patients of the Myriad Pharmaceuticals' phase III clinical trial of Flurizan (a gamma-secretase modulator) versus placebo. The original analysis of 1649 patients found no treatment group differences. HBCP analysis and the original ADAS-Cog analysis were performed on the small sample. HBCP analysis detected impaired memory storage during delayed recall, whereas the original ADAS-Cog analytical method did not. The HBCP model identified a harmful treatment effect in a small sample, which has been independently confirmed from the results of other gamma-secretase inhibitor. The original analytical method applied to the ADAS-Cog data did not detect this harmful treatment effect on either the full or the small sample. These findings suggest that HBCP models can detect treatment effects more sensitively than currently used analytical methods required by the Food and Drug Administration, and they do so using small patient samples.

Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice.[Pubmed:17650315]

BMC Neurosci. 2007 Jul 24;8:54.

BACKGROUND: Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with a reduced incidence of Alzheimer's disease (AD). We and others have shown that certain NSAIDs reduce secretion of Abeta42 in cell culture and animal models, and that the effect of NSAIDs on Abeta42 is independent of the inhibition of cyclooxygenase by these compounds. Since Abeta42 is hypothesized to be the initiating pathologic molecule in AD, the ability of these compounds to lower Abeta42 selectively may be associated with their protective effect. We have previously identified R-flurbiprofen (tarenflurbil) as a selective Abeta42 lowering agent with greatly reduced cyclooxygenase activity that shows promise for testing this hypothesis. In this study we report the effect of chronic R-flurbiprofen treatment on cognition and Abeta loads in Tg2576 APP mice. RESULTS: A four-month preventative treatment regimen with R-flurbiprofen (10 mg/kg/day) was administered to young Tg2576 mice prior to robust plaque or Abeta pathology. This treatment regimen improved spatial learning as assessed by the Morris water maze, indicated by an increased spatial bias during the third probe trial and an increased utilization of a place strategy to solve the water maze. These results are consistent with an improvement in hippocampal- and medial temporal lobe-dependent memory function. A modest, though not statistically significant, reduction in formic acid-soluble levels of Abeta was also observed. To determine if R-flurbiprofen could reverse cognitive deficits in Tg2576 mice where plaque pathology was already robust, a two-week therapeutic treatment was given to older Tg2576 mice with the same dose of R-flurbiprofen. This approach resulted in a significant decrease in Abeta plaque burden but no significant improvement in spatial learning. CONCLUSION: We have found that chronic administration of R-flurbiprofen is able to attenuate spatial learning deficits if given prior to plaque deposition in Tg2576 mice. Given its ability to selectively target Abeta42 production and improve cognitive impairments in transgenic APP mice, as well as promising data from a phase 2 human clinical trial, future studies are needed to investigate the utility of R-flurbiprofen as an AD therapeutic and its possible mechanisms of action.

NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo.[Pubmed:12897211]

J Clin Invest. 2003 Aug;112(3):440-9.

Epidemiologic studies demonstrate that long-term use of NSAIDs is associated with a reduced risk for the development of Alzheimer disease (AD). In this study, 20 commonly used NSAIDs, dapsone, and enantiomers of flurbiprofen were analyzed for their ability to lower the level of the 42-amino-acid form of amyloid beta protein (Abeta42) in a human H4 cell line. Thirteen of the NSAIDs and the enantiomers of flurbiprofen were then tested in acute dosing studies in amyloid beta protein precursor (APP) transgenic mice, and plasma and brain levels of Abeta and the drug were evaluated. These studies show that (a). eight FDA-approved NSAIDs lower Abeta42 in vivo, (b). the ability of an NSAID to lower Abeta42 levels in cell culture is highly predicative of its in vivo activity, (c). in vivo Abeta42 lowering in mice occurs at drug levels achievable in humans, and (d). there is a significant correlation between Abeta42 lowering and levels of ibuprofen. Importantly, flurbiprofen and its enantiomers selectively lower Abeta42 levels in broken cell gamma-secretase assays, indicating that these compounds directly target the gamma-secretase complex that generates Abeta from APP. Of the compounds tested, meclofenamic acid, racemic flurbiprofen, and the purified R and S enantiomers of flurbiprofen lowered Abeta42 levels to the greatest extent. Because R-flurbiprofen reduces Abeta42 levels by targeting gamma-secretase and has reduced side effects related to inhibition of cyclooxygenase (COX), it is an excellent candidate for clinical testing as an Abeta42 lowering agent.

Description

Tarenflurbil ((R)-Flurbiprofen) is the R-enantiomer of the racemate NSAID Flurbiprofen, Tarenflurbil ((R)-Flurbiprofen) inhibits the binding of [3H]9-cis-RA to RXRα LBD with IC50 of 75 μM.

Keywords:

Flurizan,51543-40-9,(<em>R</em>)-Flurbiprofen,Natural Products,Gamma Secretase, buy Flurizan , Flurizan supplier , purchase Flurizan , Flurizan cost , Flurizan manufacturer , order Flurizan , high purity Flurizan

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: